☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - October 2020

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Budesonide orodispersible (Jorveza®) has been accepted for restricted use in the treatment of eosinophilic oesophagitis (EoE) in adults (older than 18 years of age). The restriction limits use to patients unsuccessfully treated with proton pump inhibitors.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - October 2020' by emailShare 'SMC Update - October 2020' on FacebookShare 'SMC Update - October 2020' on TwitterShare 'SMC Update - October 2020' on LinkedInShare 'SMC Update - October 2020' on reddit


No Comments to “SMC Update - October 2020”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.